CPHI 2025: linker innovation paves the way for a wave of new ADCs
Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to their therapeutic payloads, are opening the door…
20 Nov 2025
Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
Merck KGaA has signed a drug discovery partnership with Valo Health, becoming the latest big pharma to enlist the services of the tech company to identify the next big therapeutic.…
20 Nov 2025
Moderna to onshore drug product manufacturing to Massachusetts
Moderna is to expand its US manufacturing capabilities with the onshoring of drug product manufacture to its existing Moderna Technology Center (MTC) in Norwood in the state of Massachusetts, in…
20 Nov 2025
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication to its label and offering a more convenient dosing option, as the…
20 Nov 2025
Novartis taps North Carolina as new manufacturing hub location
Novartis has settled on North Carolina as the home for three of its newest manufacturing facilities, which will see the company create a “flagship manufacturing hub” in the US state.…
20 Nov 2025
Pfizer and Tris agree with Texas over ADHD drug allegations
Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by Texas Attorney General Ken Paxton that they supplied adulterated attention-deficit hyperactivity disorder (ADHD) medication to children in…
20 Nov 2025
EC authorises Roche’s Lunsumio SC for follicular lymphoma
Roche has received conditional marketing authorisation from the European Commission (EC) for Lunsumio (mosunetuzumab) subcutaneous (SC) for adults with relapsed or refractory follicular lymphoma (R/R FL) after at least two…